Leukemia stem cells

Seminars in Cancer Biology

Volumn 20, Issue 2, 2010, Pages 71-76

  Lane, Steven W ^a,b   Gilliland, D Gary ^c,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer stem cells; Leukemia; Leukemia stem cells

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; GRANULOCYTE COLONY STIMULATING FACTOR; PARTHENOLIDE; PROTEASOME INHIBITOR; SALINOMYCIN; TELOMERASE; TRANSCRIPTION FACTOR HOXA9;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CYTOLOGY; DRUG MECHANISM; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; ONCOGENE; PROGNOSIS; REVIEW; RISK FACTOR; ANIMAL; PATHOLOGY;

ANIMALS; HUMANS; LEUKEMIA; NEOPLASTIC STEM CELLS;

EID: 77953808044     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.12.001     Document Type: Review

References (79)

1. Bruce W.R., Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963, 199:79-80.
2. Griffin J.D., Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986, 68:1185-1195.
3. Spangrude G.J., Heimfeld S., Weissman I.L. Purification and characterization of mouse hematopoietic stem cells. Science 1988, 241:58-62.
4. Morrison S.J., Weissman I.L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1994, 1:661-673.
5. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
6. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
7. Huntly B.J., Shigematsu H., Deguchi K., Lee B.H., Mizuno S., Duclos N., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6:587-596.
8. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
9. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
10. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
11. Deshpande A.J., Cusan M., Rawat V.P., Reuter H., Krause A., Pott C., et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 2006, 10:363-374.
12. Hu Y., Chen Y., Douglas L., Li S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23:109-116.
13. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
14. Scholl C., Bansal D., Dohner K., Eiwen K., Huntly B.J., Lee B.H., et al. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest 2007, 117:1037-1048.
15. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17:3029-3035.
16. Kirstetter P., Schuster M.B., Bereshchenko O., Moore S., Dvinge H., Kurz E., et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 2008, 13:299-310.
17. Guibal F.C., Alberich-Jorda M., Hirai H., Ebralidze A., Levantini E., Di Ruscio A., et al. Identification of a myeloid committed progenitor as the cancer initiating cell in acute promyelocytic leukemia. Blood 2009.
18. Wojiski S., Guibal F.C., Kindler T., Lee B.H., Jesneck J.L., Fabian A., et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009, 23:1462-1471.
19. Chen W., Kumar A.R., Hudson W.A., Li Q., Wu B., Staggs R.A., et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 2008, 13:432-440.
20. Neering S.J., Bushnell T., Sozer S., Ashton J., Rossi R.M., Wang P.Y., et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 2007, 110:2578-2585.
21. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
22. Blair A., Hogge D.E., Ailles L.E., Lansdorp P.M., Sutherland H.J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997, 89:3104-3112.
23. Miyamoto T., Weissman I.L., Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000, 97:7521-7526.
24. Bereshchenko O., Mancini E., Moore S., Bilbao D., Mansson R., Luc S., et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell 2009, 16:390-400.
25. Hong D., Gupta R., Ancliff P., Atzberger A., Brown J., Soneji S., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008, 319:336-339.
26. Mullighan C.G., Phillips L.A., Su X., Ma J., Miller C.B., Shurtleff S.A., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
27. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104:10158-10163.
28. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
29. Mahadevan D., List A.F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004, 104:1940-1951.
30. Heidel F., Solem F.K., Breitenbuecher F., Lipka D.B., Kasper S., Thiede M.H., et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006, 107:293-300.
31. Lessard J., Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260.
32. Zhao C., Blum J., Chen A., Kwon H.Y., Jung S.H., Cook J.M., et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528-541.
33. Dierks C., Beigi R., Guo G.R., Zirlik K., Stegert M.R., Manley P., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
34. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
35. Ferrando A.A., Armstrong S.A., Neuberg D.S., Sallan S.E., Silverman L.B., Korsmeyer S.J., et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003, 102:262-268.
36. Hofmann I., Stover E.H., Cullen D.E., Mao J., Morgan K.J., Lee B.H., et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009, 4:559-567.
37. Guzman M.L., Rossi R.M., Karnischky L., Li X., Peterson D.R., Howard D.S., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163-4169.
38. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
39. Costello R.T., Mallet F., Gaugler B., Sainty D., Arnoulet C., Gastaut J.A., et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000, 60:4403-4411.
40. Morrison S.J., Prowse K.R., Ho P., Weissman I.L. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 1996, 5:207-216.
41. Drummond M.W., Hoare S.F., Monaghan A., Graham S.M., Alcorn M.J., Keith W.N., et al. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia 2005, 19:381-389.
42. Campbell L.J., Fidler C., Eagleton H., Peniket A., Kusec R., Gal S., et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006, 20:671-679.
43. Bernard L., Belisle C., Mollica L., Provost S., Roy D.C., Gilliland D.G., et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia 2009, 23:287-291.
44. Kirwan M., Vulliamy T., Marrone A., Walne A.J., Beswick R., Hillmen P., et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009, 30:1567-1573.
45. Chakraborty S., Sun C.L., Francisco L., Sabado M., Li L., Chang K.L., et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009, 27:791-798.
46. Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
47. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
48. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche-current concepts and therapeutic opportunities. Blood 2009.
49. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
50. Iwamoto S., Mihara K., Downing J.R., Pui C.H., Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007, 117:1049-1057.
51. Wei J., Wunderlich M., Fox C., Alvarez S., Cigudosa J.C., Wilhelm J.S., et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008, 13:483-495.
52. Walkley C.R., Olsen G.H., Dworkin S., Fabb S.A., Swann J., McArthur G.A., et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007, 129:1097-1110.
53. Walkley C.R., Shea J.M., Sims N.A., Purton L.E., Orkin S.H. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007, 129:1081-1095.
54. Colmone A., Amorim M., Pontier A.L., Wang S., Jablonski E., Sipkins D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322:1861-1865.
55. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123 IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
56. Hosen N., Park C.Y., Tatsumi N., Oji Y., Sugiyama H., Gramatzki M., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007, 104:11008-11013.
57. van Rhenen A., Feller N., Kelder A., Westra A.H., Rombouts E., Zweegman S., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
58. Monaco G., Konopleva M., Munsell M., Leysath C., Wang R.Y., Jackson C.E., et al. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 2004, 22:188-201.
59. Schlenk R.F., Dohner K., Krauter J., Frohling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
60. Cheung A.M., Wan T.S., Leung J.C., Chan L.Y., Huang H., Kwong Y.L., et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21:1423-1430.
61. Krause D.S., Lazarides K., von Andrian U.H., Van Etten R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006, 12:1175-1180.
62. Ito K., Bernardi R., Morotti A., Matsuoka S., Saglio G., Ikeda Y., et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-1078.
63. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
64. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
65. Guzman M.L., Rossi R.M., Neelakantan S., Li X., Corbett C.A., Hassane D.C., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435.
66. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
67. Zeng Z., Shi Y.X., Samudio I.J., Wang R.Y., Ling X., Frolova O., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
68. Lowenberg B., van Putten W., Theobald M., Gmur J., Verdonck L., Sonneveld P., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
69. Liesveld J.L., Rosell K.E., Lu C., Bechelli J., Phillips G., Lancet J.E., et al. Acute myelogenous leukemia-microenvironment interactions: role of endothelial cells and proteasome inhibition. Hematology 2005, 10:483-494.
70. Ploemacher R.E., van der Sluijs J.P., Voerman J.S., Brons N.H. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood 1989, 74:2755-2763.
71. Moore K.A., Ema H., Lemischka I.R. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997, 89:4337-4347.
72. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
73. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
74. Adams J.M., Kelly P.N., Dakic A., Carotta S., Nutt S.L., Strasser A. Role of " cancer stem cells" and cell survival in tumor development and maintenance. Cold Spring Harb Symp Quant Biol 2008, 73:451-459.
75. Abrahamsson A.E., Geron I., Gotlib J., Dao K.H., Barroga C.F., Newton I.G., et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009, 106:3925-3929.
76. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667.
77. Taussig D.C., Miraki-Moud F., Anjos-Afonso F., Pearce D.J., Allen K., Ridler C., et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008, 112:568-575.
78. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
79. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.